| 名稱 | Lapatinib |
| 描述 | Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression. |
| 細胞實驗 | Cells are plated in 96-well plates, in the media, at the following densities: HFF and HN5, 1000 cells/well and BT474, 5000 cells/well. After 24 h, the cells are exposed to vehicle (0.3% DMSO) or Lapatinib (1 nM, 10 nM, 100 nM, 1μM, 10μM, and 100μM). Lapatinib is removed from the cells after 72 h and is replaced by either DMEM containing 10% FBS and 50 μg/mL Gentamicin (HFF and HN5) or RPMI containing 10% FBS and 50 μg/mL Gentamicin (BT474). Methylene blue staining is performed at the time points over a total period of 16 days. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide [1]. |
| 激酶實驗 | The IC50 values for inhibition of enzyme activity are generated by measuring the inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves [1]. |
| 動物實驗 | CD-1 nude female mice are used for HN5 human tumor xenografts, which are initiated by injection of a cell suspension in PBS: Matrigel (1:1). C.B-17 SCID female mice are used for BT474 human tumor xenografts, which are initiated by implantation of tumor fragments (20-100 mg) from established tumors. Tumor cells and fragments are implanted by s.c. injection in the right flank. The s.c. tumors are measured with calipers, and mice are weighed twice weekly. Tumor weight is estimated from tumor volume using this formula: length×width2/2=tumor volume (mm3). Treatment begins when tumors are palpable, 3-5 mm in diameter. Lapatinib (30 and 100 mg/kg) is administered p.o. twice daily for 21 days in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10) [1]. |
| 體外活性 | 方法：14 株人胃癌和食管癌細胞系用 Lapatinib (0.3125-10 μmol/L) 處理 6 天，使用 particle counter 檢測細胞數(shù)。
結果：N87、OE19、NUGC4、NUGC3、FU97、SNU16 細胞對 Lapatinib 敏感，IC50 分別為 0.01、0.09、0.35、2.24、4.86、8.58 μmol/L。[1]
方法：人乳腺癌細胞 MDA-MB-231 和 SK-BR-3 用 Lapatinib (0.5-2 μM) 處理 48 h，使用 Western Blot 方法檢測靶點蛋白表達水平。
結果：與較低濃度相比，用 1.0 μM Lapatinib 處理的 MDA-MB-231 和 SK-BR-3 細胞系中 PKM2 的表達均顯著降低。[2] |
| 體內活性 | 方法：為檢測體內抗腫瘤活性，將 Lapatinib (100 mg/kg) 腹腔注射給攜帶人胃癌腫瘤 N87 的 CD-1 athymic nude 小鼠，每天一次，持續(xù)三周。
結果：Lapatinib 導致 N87 異種移植物的腫瘤消退。[1]
方法：為檢測體內抗腫瘤活性，將 Lapatinib (30-100 mg/kg，灌胃給藥，每天兩次持續(xù)二十一天) 和 Topoteca (6-10 mg/kg，腹腔注射，每四天一次持續(xù)三次) 灌胃給藥給攜帶人乳腺癌腫瘤 BT474 的 SCID 小鼠。
結果：Lapatinib 和 Topoteca 組合在 ER2+BT474 異種移植物中顯示出增強的功效。[3] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 18.33 mg/mL (31.55 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9.3 mg/mL (16.01 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| 關鍵字 | GW 572016 | GW-2016 | GSK-572016 | GW 2016 | HER1 | Inhibitor | EGFR | Autophagy | ErbB-1 | Ferroptosis | inhibit | GW-572016 | GW2016 | GSK 572016 | Epidermal growth factor receptor | Lapatinib |
| 相關產(chǎn)品 | L-Cystine | Guanidine hydrochloride | Naringin | Valproic Acid | L-Glutamic acid | Gefitinib | Aceglutamide | Hydroxychloroquine | Stavudine | Acetylcysteine | Paeonol | Sodium 4-phenylbutyrate |
| 相關庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 抗癌上市藥物庫 | 已知活性化合物庫 | EMA 上市藥物庫 | 抗衰老化合物庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 抗癌臨床化合物庫 |